<DOC>
	<DOCNO>NCT01307033</DOCNO>
	<brief_summary>This study conduct evaluate safety MK-0954A ( L100/H12.5 mg ) essential hypertension participant uncontrolled MK-954H ( L50/H12.5 mg ) .</brief_summary>
	<brief_title>A Long-term Study Safety MK-0954A Patients With Essential Hypertension ( MK-0954A-351 )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Inclusion criterion : Participant diagnosis essential hypertension . Participant treat single , dual combination treatment hypertension able discontinue prior antihypertensive medication . Participant mean trough SiDBP &gt; =90mmHg &lt; 110mmHg . Participant mean trough SiSBP &gt; =140mmHg &lt; 200mmHg . Participant clinically significant abnormality screen visit . Exclusion criterion : Participant currently take &gt; 2 antihypertensive medication . Participant history significant multiple and/or severe allergy ingredient Nulotan Preminent thiazide drug relate drug ( i.e. , sulfonamidecontaining `` chlortalidone '' medicine ) . Participant , time signing informed consent , user recreational illicit drug recent history within last year drug alcohol abuse dependence . Participant pregnant breastfeeding , expect conceive pregnancy test positive screening visit . Participant currently participate participate study investigational compound device within 30 day sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>Uncontrolled hypertension</keyword>
	<keyword>Antihypertensive agent</keyword>
	<keyword>Blood pressure</keyword>
</DOC>